Alaunos Therapeutics, Inc.
TCRTHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeAlaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. At a $4.1M market cap, Alaunos Therapeutics, Inc. ranks as a micro-cap company within healthcare. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Market Cap
$4.1M
Beta
-0.97
P/E (TTM)
—
P/E (Fwd)
-2.72
EPS (TTM)
$-1.75
EPS (Fwd)
$-0.60
ROE
-185.9%
ROA
-81.1%
Cash
$124,000
Total Debt
$0
Free CF
-$1.6M
52W Change
-29.1%
Annual Financials
Cash vs Debt
Where TCRT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TCRT finished 32.93% below its 150-day moving average ($2.49) and 38.38% below its 200-day moving average ($2.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TCRT overbought or oversold?
At the September 3, 2026 close, TCRT's RSI(14) was 25.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alaunos Therapeutics, Inc. reports $124K in cash and $0 in total debt. Free cash flow is running at -$1.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -185.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $2.9M (2022) to $5K (2025), a 100% decline worth watching.
TCRT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TCRT.